Tuscan Rock Thompson

This study designs de novo cysteine proteases with high activity and structural novelty, achieving 19% success rate and up to 3 x 10^7 rate enhancement over background reactions.

This study designs miniprotein inhibitors targeting bacterial adhesins to prevent and treat urinary tract infections.

RFOptimization improves all-atom biomolecular binder design by combining gradient-guided sequence optimization with orthogonal predictors to enhance in silico success rates.

An all-atom diffusion model using a 14-atom residue representation and sparse U-Net architecture accelerates biomolecular design 10-fold, enabling experimentally validated DNA-binding proteins and multi-turnover cysteine hydrolases.